Activated clotting time systems vary in precision and bias and are not interchangeable when following heparin management protocols during cardiopulmonary bypass

被引：24

作者：

Welsby I.J. ^{[1
]}

McDonnell E. ^{[2
]}

El-Moalem H. ^{[1
]}

Stafford-Smith M. ^{[1
]}

Toffaletti J.G. ^{[2
]}

机构：

[1] Department of Anesthesiology, Duke University, Medical Center, Durham

[2] Department of Pathology, Duke University, Medical Center, Durham

来源：

Journal of Clinical Monitoring and Computing | 2002年 / 17卷 / 05期

关键词：

Angioplasty; Blood coagulation tests/mt [methods; Cardiopulmonary bypass; Equipment design; Heparin/ad [administration & dosage; Human; Percutaneous coronary; Transluminal; Whole blood coagulation time;

D O I：

10.1023/A:1021298103264

中图分类号：

学科分类号：

摘要：

Objective. Our aim was to test the hypothesis that new activated clotting time (ACT) technology, with modifications to instruments and reagents designed to detect earlier clot formation, would be associated with more precise but lower results. A secondary objective was to evaluate the potential impact of any change in ACT measurement on heparin requirements during cardiopulmonary bypass (CPB). Methods. We compared the precision of two newer ACT systems: Actalyke®, Helena Laboratories, Beaumont, TX and Hemochron Response®, International Technidyne Corporation, Edison, NJ and assessed their bias with reference to a standard ACT system (Hemochron 801, International Technidyne Corporation, Edison, NJ). Bland-Altman analysis was applied to 81 duplicate samples from 22 patients undergoing CPB or percutaneous coronary interventions (PCI), covering the full clinical range of ACT values. We also estimated the change in heparin dose required to use the Actalyke® rather than the Hemochron 801 results, to achieve our target ACT for CPB (480 seconds), and used a mixed model to test for significance. Results. The precision of the Actalyke® was superior to the Hemochron Response® (mean difference of duplicates ± 0.1% versus ± 4.2%). There was no significant bias (p = 0.93) between the results from the standard analyzers (Hemochron 801 and Response®), but the results from the modified system (Actalyke®) were on average 18% lower than the Hemochron 801 (p < 0.0001). Estimated heparin requirements established that fifty percent of CPB patients would have required additional heparin (5000 to 17500 units), an average increase of 1060 units per patient (p = 0.05), if the Actalyke® values were used to guide anticoagulation during CPB. Conclusions. Our results support the hypothesis that the modified technology (Actalyke®) is associated with more precise but lower ACT results. We estimated these lower values would lead to increased heparin dosing during CPB. The impact of this increase on bleeding after cardiac surgery with CPB is controversial and requires further study.

引用

页码：287 / 292

页数：5

共 18 条

[1]

Bull B.S., Korpman R.A., Huse W.M., Briggs B.D., Heparin therapy during extracorporeal circulation: I, J Thorac Cardiovasc Surg, 69, 5, pp. 674-684, (1975)

[2]

Hattersley P.C., Activated coagulation time of whole blood, JAMA, 196, pp. 436-444, (1966)

[3]

Niinikoski J., Laato M., Laaksonen V., Jalonen J., Inberg M.V., Use of activated clotting time to monitor anticoagulation during cardiac surgery, Scand J Thorac Cardiovasc Surg, 18, 1, pp. 57-61, (1984)

[4]

Akl B.F., Vargas G.M., Neal J., Robillard J., Kelly P., Clinical experience with the activated clotting time for the control of heparin and protamine therapy during cardiopulmonary bypass, J Thorac Cardiovasc Surg, 79, 1, pp. 97-102, (1980)

[5]

Preiss D.U., Schmidt-Bleibtreu H., Berguson P., Metz G., Blood transfusion requirements in coronary artery surgery with and without the activated clotting time (ACT) technique, Klin Wochenschr, 63, 6, pp. 252-256, (1985)

[6]

Verska J.J., Control of heparinization by activated clotting time during bypass with improved postoperative hemostasis, Ann Thorac Surg, 24, 2, pp. 170-173, (1977)

[7]

Despotis G.J., Joist J.H., Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: An update, J Cardiothorac Vasc Anesth, 13, 4 SUPPL. 1, pp. 18-29, (1999)

[8]

Bull B.S., Korpman R.A., Huse W.M., Briggs B.D., Heparin therapy during extracorporeal circulation: II, J Thorac Cardiovasc Surg, 69, 5, pp. 685-689, (1975)

[9]

Young J.A., Kisker C.T., Doty D.B., Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer, Ann Thorac Surg, 26, 3, pp. 231-240, (1978)

[10]

Reich D.L., Zhal K., Perucho M.H., Thys D.M., An evaluation of two activated clotting time monitors during cardiac surgery, J Clin Monit, 8, 1, pp. 33-36, (1992)

← 1 2 →